Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


Debiopharm, Nobelex Biotech collaborate

Thursday, June 26, 2014 02:14 PM

Debiopharm Group, a Switzerland-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, and Nobelex Biotech, a Canadian company focusing on the discovery and early development of novel antimicrobial drugs, are collaborating on two discovery programs to develop antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action.

More... »

WIRB Copernicus Group

BioOutsource to open a Massachusetts lab facility in 2015

Thursday, June 26, 2014 02:13 PM

BioOutsource, a global provider of biologics contract testing and biosimilar characterization for the biopharmaceutical industry, plans to open a new North American testing facility in 2015. The last year has been an exceptional growth year for the company: global demand for outsourced testing services, coupled with BioOutsource’s continued investment in R&D and the opening of a BioSimilar Center of Excellence in Glasgow in February, has created the need to establish a new testing facility.

More... »

CRF Health eCOA webinar series

Regional Immunotherapy Discovery Program launched by Northeast cancer centers

Thursday, June 26, 2014 02:10 PM

Physician researchers from Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., and John Theurer Cancer Center (JTCC) in Hackensack, N.J., have formed the Regional Immunotherapy Discovery Program.

More... »

Applikon Biotechnology, SecureCell collaborate

Thursday, June 26, 2014 02:09 PM

Applikon Biotechnology and SecureCell have signed an agreement for the worldwide marketing and sales of Advanced Process Information Management Software developed by SecureCell. The software allows the user to monitor and control bioprocesses and offers an extensive toolbox for analyzing process data cross platforms. Process information is generated based on data from different brands of bioreactors and a wide range of different cultivation volumes.

More... »

Johnson & Johnson, Dana-Farber launch $10 million lung cancer collaboration

Thursday, June 26, 2014 02:03 PM

Johnson & Johnson Innovation, Boston, and Janssen Biotech have announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline.

More... »

Affymax to dissolve company

Thursday, June 26, 2014 01:52 PM

The board of directors of biopharmaceutical company Affymax has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders.

More... »

IMS Health acquires Cegedim’s CRM and software developer unit

Thursday, June 26, 2014 12:45 PM

IMS Health, which in the last year has been actively making acquisitions leading up to its April IPO, has announced its intention to acquire Paris-based Cegedim’s information solutions and customer relationship management (CRM) business for approximately $520 million in cash.

More... »

Bristol-Myers Squibb, Duke Clinical Research Institute collaborate

Wednesday, June 25, 2014 02:15 PM

Bristol-Myers Squibb is collaborating with Duke University through its Duke Clinical Research Institute (DCRI), focusing on clinical trial transparency. BMS will expand access to a broader set of clinical trial information from in-scope, company-sponsored studies and enable an independent scientific review through DCRI of requests from researchers that meet pre-specified requirements.

More... »

AbbVie outlines rationale for Shire offer

Wednesday, June 25, 2014 02:14 PM

Following Shire’s confirmed rejection of Abbvie’s offer on June 20, AbbVie has outlined its strategic rationale for, and background to, its proposal to the board of Shire of $34.74 in cash and 0.7988 ordinary shares of New AbbVie for each Shire share. The proposal represented an indicative value of $78.63 on May 29 (the latest practicable date before the proposal was made). While this cash and share mix is valued at $77.57 per share as of June 24, any firm offer made by AbbVie under Rule 2.7 of the Code will need to be equivalent to $78.63 per share.

More... »

Report: Global biotechnology industry needs new paradigm for drug R&D

Wednesday, June 25, 2014 02:11 PM

The global biotechnology industry rebounded strongly in 2013, with public companies achieving double-digit revenue growth and a sharp increase in funds raised. However, much of the industry's growth was driven by a relatively small group of commercial stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts. These are some of the key findings of Beyond borders: unlocking value, EY's 28th annual biotechnology industry report.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs